Economic burden of lung cancer in Morocco: A cost of illness study

IF 2 Q3 HEALTH POLICY & SERVICES
I. El Harch , S. Guendaoui , M. Charkaoui , S. Benmaamar , M. Omari , M. EL Youbi , L. Belakhhel , L. Abouselham , H. Hachri , I. El Menchay , S. El Fakir , M. Berraho , N. Benchekroun , N. Tachfouti
{"title":"Economic burden of lung cancer in Morocco: A cost of illness study","authors":"I. El Harch ,&nbsp;S. Guendaoui ,&nbsp;M. Charkaoui ,&nbsp;S. Benmaamar ,&nbsp;M. Omari ,&nbsp;M. EL Youbi ,&nbsp;L. Belakhhel ,&nbsp;L. Abouselham ,&nbsp;H. Hachri ,&nbsp;I. El Menchay ,&nbsp;S. El Fakir ,&nbsp;M. Berraho ,&nbsp;N. Benchekroun ,&nbsp;N. Tachfouti","doi":"10.1016/j.jcpo.2023.100428","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Lung cancer is the most common cancer in men and the second most common cancer in women. It is associated with substantial economic impact in terms of direct and indirect costs. The main objective of this study is to estimate the direct medical cost of lung cancer management in Morocco</p></div><div><h3>Materials and methods</h3><p>A cost-of-illness study was conducted among patients treated at the Mohammed VI Center of Cancer (Casablanca) in 2019. The costs were estimated from the societal perspective using a bottom-up approach. The materials and procedures used were identified and quantified retrospectively from the information system and files. Their monetary value was calculated according to official prices published by the national health insurance agency. The horizon time adopted was 12 months.</p></div><div><h3>Results</h3><p>The study included 271 patients, with an average age of 62.5 ± 9.5 years. Of these, 93.4 % were men and 92.1 % were former smokers. In terms of cancer staging, 68.3 % of patients were in stage IV while 28.8 % were in stage III. Adenocarcinoma was present in 43.5 % of cases. Patients underwent an average of 10.6 ± 5.1 radiological investigations, 56.1 ± 30.9 biological tests, and 24.1 ± 11.7 consultations.</p><p>The average direct medical cost was 4455.3 USD (95 % CI: 4037.4–4873.2). Chemotherapy accounted for 19.9 % of the total cost, while radiological investigations and drugs accounted for 18.7 % and 17.6 %, respectively. Diagnostic tests and radiotherapy each accounted for 7.6 % of the total cost, while biological tests accounted for 7.5 % and hospitalizations accounted for 7.1 %.</p><p>The cost was statistically higher in young patients (p = 0.017), in patients with adenocarcinoma (p &lt; 0.0001), in patients with stage II tumor (&lt; 0.00001), in patients who have undergone surgery (p = 0.002), chemotherapy (p &lt; 0.0001), radiotherapy (p &lt; 0.001) and in those without metastases (p &lt; 0.0001).</p></div><div><h3>Conclusion</h3><p>These results provide evidence to support the ratification of the Framework Convention on Tobacco Control and the full adherence of the Kingdom of Morocco to the MPOWER measures.</p></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer Policy","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213538323000450","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEALTH POLICY & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction

Lung cancer is the most common cancer in men and the second most common cancer in women. It is associated with substantial economic impact in terms of direct and indirect costs. The main objective of this study is to estimate the direct medical cost of lung cancer management in Morocco

Materials and methods

A cost-of-illness study was conducted among patients treated at the Mohammed VI Center of Cancer (Casablanca) in 2019. The costs were estimated from the societal perspective using a bottom-up approach. The materials and procedures used were identified and quantified retrospectively from the information system and files. Their monetary value was calculated according to official prices published by the national health insurance agency. The horizon time adopted was 12 months.

Results

The study included 271 patients, with an average age of 62.5 ± 9.5 years. Of these, 93.4 % were men and 92.1 % were former smokers. In terms of cancer staging, 68.3 % of patients were in stage IV while 28.8 % were in stage III. Adenocarcinoma was present in 43.5 % of cases. Patients underwent an average of 10.6 ± 5.1 radiological investigations, 56.1 ± 30.9 biological tests, and 24.1 ± 11.7 consultations.

The average direct medical cost was 4455.3 USD (95 % CI: 4037.4–4873.2). Chemotherapy accounted for 19.9 % of the total cost, while radiological investigations and drugs accounted for 18.7 % and 17.6 %, respectively. Diagnostic tests and radiotherapy each accounted for 7.6 % of the total cost, while biological tests accounted for 7.5 % and hospitalizations accounted for 7.1 %.

The cost was statistically higher in young patients (p = 0.017), in patients with adenocarcinoma (p < 0.0001), in patients with stage II tumor (< 0.00001), in patients who have undergone surgery (p = 0.002), chemotherapy (p < 0.0001), radiotherapy (p < 0.001) and in those without metastases (p < 0.0001).

Conclusion

These results provide evidence to support the ratification of the Framework Convention on Tobacco Control and the full adherence of the Kingdom of Morocco to the MPOWER measures.

摩洛哥癌症的经济负担:疾病成本研究
简介癌症是男性最常见的癌症,女性第二常见的癌症。它与直接和间接成本方面的巨大经济影响有关。本研究的主要目的是估计摩洛哥癌症治疗的直接医疗成本材料和方法2019年在癌症穆罕默德六世中心(卡萨布兰卡)接受治疗的患者中进行了一项疾病成本研究。成本是从社会角度使用自下而上的方法估算的。所使用的材料和程序是从信息系统和文件中回顾性地确定和量化的。它们的货币价值是根据国家健康保险机构公布的官方价格计算的。采用的地平线时间为12个月。结果271例患者,平均年龄62.5±9.5岁。其中男性占93.4%,前吸烟者占92.1%。就癌症分期而言,68.3%的患者处于IV期,28.8%的患者处于III期。43.5%的病例中存在腺癌。患者平均接受了10.6±5.1次放射学检查、56.1±30.9次生物检查和24.1±11.7次会诊。平均直接医疗费用为4455.3美元(95%置信区间:4037.4–4873.2)。化疗占总费用的19.9%,放射检查和药物分别占18.7%和17.6%。诊断检查和放射治疗各占总费用的7.6%,而生物检查占7.5%,住院治疗占7.1%。年轻患者(p=0.017)、腺癌患者(p<0.0001)、II期肿瘤患者(<0.00001)、接受过手术的患者(p=0.002)的费用在统计学上更高,化疗(p<0.0001)、放疗(p<0.001)和无转移患者(p<.0001)。结论这些结果为批准《烟草控制框架公约》和摩洛哥王国全面遵守MPOWER措施提供了证据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Cancer Policy
Journal of Cancer Policy Medicine-Health Policy
CiteScore
2.40
自引率
7.70%
发文量
47
审稿时长
65 days
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信